Advertisement

Topics

Clinical Trials About "Influence Ankylosing Spondylitis phenotype results from REGISPONSER database" RSS

15:39 EDT 18th March 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Influence Ankylosing Spondylitis phenotype results from REGISPONSER database" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Influence Ankylosing Spondylitis phenotype results from REGISPONSER database" on BioPortfolio

We have published hundreds of Influence Ankylosing Spondylitis phenotype results from REGISPONSER database news stories on BioPortfolio along with dozens of Influence Ankylosing Spondylitis phenotype results from REGISPONSER database Clinical Trials and PubMed Articles about Influence Ankylosing Spondylitis phenotype results from REGISPONSER database for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Influence Ankylosing Spondylitis phenotype results from REGISPONSER database Companies in our database. You can also find out about relevant Influence Ankylosing Spondylitis phenotype results from REGISPONSER database Drugs and Medications on this site too.

Showing "Influence Ankylosing Spondylitis phenotype results from REGISPONSER database" Clinical Trials 1–25 of 12,000+

Extremely Relevant

Increasing Physical Activity in Ankylosing Spondylitis: a Randomised Controlled Trial

Ankylosing spondylitis is a chronic inflammatory condition that mostly affects the spine. This results in back pain and stiffness, and causes difficulty with daily activities. Physical activity and exercise are key components of the management of ankylosing spondylitis, however many adults with ankylosing spondylitis do not meet physical activity recommendations. This study aims to investigate the effects of a twelve week intervention designed to increase physical activity and ...


Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis

This is an open-label trial investigating the efficacy and safety of abatacept in ankylosing spondylitis. It is planned to treat 30 patients with ankylosing spondylitis from baseline up to week 30. Abatacept will be administered intravenously according to the prescription used in rheumatoid arthritis.

A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)

The objectives of this prospective observational study is to explore 1-year clinical response via both Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) after initiation of adalimumab therapy in AS patients from routine clinical practices in Taiwan.


Clinical Trial of Osteoporosis in Ankylosing Spondylitis

This is an observational study aiming to study the prevalence and risk factors for osteoporosis and vertebral fractures in patients with ankylosing spondylitis attending three Rheumatology clinics in Western Sweden.

16.0040 Ankylosing Spondylitis Study

The purpose of this study was to evaluate extended safety and efficacy of etanercept in adults with Ankylosing Spondylitis.

Investigation of 9 Consecutive Remicade Infusions in Ankylosing Spondylitis in Austria (Study P04044)(COMPLETED)

This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time span of Remicade between infusions for ankylosing spondylitis (AS).

Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis

The current study will assess the real - life effectiveness of adalimumab in the management of Ankylosing Spondylitis (AS) with emphasis on the prevention and management of extra-articular manifestations.

Stretching in Water and on Land for Patients With Ankylosing Spondylitis

The aim of the study is to investigate the effectiveness stretching exercises in ankylosing spondylitis.

Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)

The study is intended to provide additional post-marketing safety data regarding the use of etoricoxib for the indication of ankylosing spondylitis.

An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis

This study is an extension trial of 0881A3-312-EU and is designed to provide information on the safety and efficacy of etanercept in patients with ankylosing spondylitis for up to 3 additional years.

Study Evaluating Etanercept Treatment of Patients With Ankylosing Spondylitis

The primary objective of the study was to compare the efficacy of etanercept (25 mg, twice weekly) with that of placebo based on the percentage of patients who achieve the Assessment in Ankylosing Spondylitis (ASAS) response criteria (ASAS 20%) at week 12.

Extension Study Evaluating Etanercept in Ankylosing Spondylitis

The primary purpose of this study is to evaluate the health care resource utilization and work status of patients with ankylosing spondylitis undergoing treatment with etanercept by comparing study evaluations with the baseline evaluations in the ASCEND (0881A3-402-WW)study.

Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis

BCD-085-3 is a next step in clinical investigation of BCD-085. BCD-085 is a monoclonal antibody to interleukin 17. During BCD-085-2 trial patients with active ankylosing spondylitis will receive 40, 80 or 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12. Efficacy and safety parameters will be evaluated.

The Effect of Acupotome in Treating Ankylosing Spondylitis

The purpose of this study is to evaluate the efficiency and safety of Acupotome in Treating Ankylosing Spondylitis.

Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis

To evaluate the efficacy and safety of rituximab when added to NSAIDs and/ or methotrexate both for TNFalpha inhibitor naïve or TNFalpha inhibitor failure patients with moderate to severe ankylosing spondylitis

Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)(COMPLETED)

This is a randomized, double-blind, multi-center, placebo-controlled study with two parallel treatment groups (placebo and infliximab) in subjects with ankylosing spondylitis (AS) to evaluate the efficacy of infliximab 3 mg/kg.

Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)

This is a Phase 4, multi-center, open-label, one-arm, pilot study in patients with active ankylosing spondylitis refractory to conventional treatment. Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54. The number of patients showing ASAS-20 clinical response at Week 14 will be evaluated.

Genetic Determinants of Ankylosing Spondylitis Severity

This study will explore how genes units of heredity may influence the severity of ankylosing spondylitis. It will examine whether some genes may cause people with ankylosing spondylitis to have more rapid fusion of the bones of the spine, more difficulty performing daily activities, or be more likely to need joint surgery. Patients who developed ankylosing spondylitis after age 16 and have had the disease for 20 years or more may be eligible for this study. The onset of ...

Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

Primary Objective: - To assess the long term safety of SAR153191 in patients with ankylosing spondylitis Secondary Objective: - To assess the long term efficacy of SAR153191 in patients with ankylosing spondylitis

Study Comparing Etanercept 50 mg Once Weekly to 25 mg Twice Weekly in Patients With Ankylosing Spondylitis

The purpose of this study is to compare efficacy, pharmacokinetics, and safety of investigational formulations of etanercept administered as 50 mg once weekly with 25 mg twice weekly and placebo in patients with ankylosing spondylitis (AS).

Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis

This study is aimed at investigation of efficacy and safety of ustekinumab (monoclonal antibody against interleukin 12 and 23) treatment in patients with active ankylosing spondylitis (AS) fulfilling the modified New York criteria who have had an inadequate response to standard therapy with non-steroidal anti-inflammatory drugs (NSAIDs) or do not tolerate or have a contraindication for NSAIDs.

A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.

A study of the safety and efficacy of Infliximab (Remicade) versus placebo in subjects with Ankylosing Spondylitis

A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.

A study of the safety and efficacy of Infliximab (Remicade) versus placebo in subjects with Ankylosing Spondylitis

Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis

This study is designed as an extension study to the proof-of-concept trial CAIN457A2209 in patients with moderate to severe ankylosing spondylitis and aims to provide continuous treatment with AIN457 for patients in the core trial, to obtain safety and tolerability information. The study will address the evaluation of efficacy following doses of 3 mg/kg AIN457 given every 4 weeks over a period initially up to 6 months (Part 1) and based on the risk/benefit balance of AIN457 in...

Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

Primary objective of the study: - to evaluate the efficacy by (ASAS20) (Assessment in Ankylosing Spondylitis Working Group responses criteria) of SAR153191 in patients with AS (Ankylosing Spondylitis) The secondary objectives are: - assessment of higher level of response ASAS40 - partial remission - disease activity - range of motion - changes in Magnetic Resonance Imaging (MRI) score - the safety and tolerability of SAR153191 i...


More From BioPortfolio on "Influence Ankylosing Spondylitis phenotype results from REGISPONSER database"

Advertisement
Quick Search
Advertisement
Advertisement